Bowman Miao
Bristol-Myers Squibb (Germany)(DE)Bristol-Myers Squibb (United States)(US)
Publications by Year
Research Areas
Peroxisome Proliferator-Activated Receptors, Adipose Tissue and Metabolism, Lipoproteins and Cardiovascular Health, Drug Transport and Resistance Mechanisms, Cholesterol and Lipid Metabolism
Most-Cited Works
- → Generation of multiple farnesoid-X-receptor isoforms through the use of alternative promoters(2002)208 cited
- → Raising HDL cholesterol without inducing hepatic steatosis and hypertriglyceridemia by a selective LXR modulator(2004)186 cited
- → Pharmacologic Profile of the Adnectin BMS-962476, a Small Protein Biologic Alternative to PCSK9 Antibodies for Low-Density Lipoprotein Lowering(2014)128 cited
- → Annexin A2 Is a Natural Extrahepatic Inhibitor of the PCSK9-Induced LDL Receptor Degradation(2012)122 cited
- → Effects of the Prosegment and pH on the Activity of PCSK9(2010)64 cited
- → Retinoid X Receptor (RXR) Agonist-induced Antagonism of Farnesoid X Receptor (FXR) Activity due to Absence of Coactivator Recruitment and Decreased DNA Binding(2003)62 cited
- → Ligand and coactivator recruitment preferences of peroxisome proliferator activated receptor α(2002)41 cited
- → Discovery of an Oxybenzylglycine Based Peroxisome Proliferator Activated Receptor α Selective Agonist 2-((3-((2-(4-Chlorophenyl)-5-methyloxazol-4-yl)methoxy)benzyl)(methoxycarbonyl)amino)acetic Acid (BMS-687453)(2010)40 cited
- → Novel Peroxisome Proliferator-Activated Receptor α Agonists Lower Low-Density Lipoprotein and Triglycerides, Raise High-Density Lipoprotein, and Synergistically Increase Cholesterol Excretion with a Liver X Receptor Agonist(2008)35 cited
- → Synthesis and structure–activity relationships of 2-aryl-4-oxazolylmethoxy benzylglycines and 2-aryl-4-thiazolylmethoxy benzylglycines as novel, potent PPARα selective activators- PPARα and PPARγ selectivity modulation(2010)10 cited